GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PetMed Express Inc (NAS:PETS) » Definitions » Cash Flow from Financing

PetMed Express (PetMed Express) Cash Flow from Financing : $-18.6 Mil (TTM As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is PetMed Express Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, PetMed Express paid $0.0 Mil more to buy back shares than it received from issuing new shares. It received $0.0 Mil from issuing more debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $0.0 Mil paying cash dividends to shareholders. It received $0.0 Mil on other financial activities. In all, PetMed Express spent $0.0 Mil on financial activities for the three months ended in Dec. 2023.


PetMed Express Cash Flow from Financing Historical Data

The historical data trend for PetMed Express's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetMed Express Cash Flow from Financing Chart

PetMed Express Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.93 -33.30 -22.69 -24.38 -24.54

PetMed Express Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.10 -6.14 -6.10 -6.30 -0.02

PetMed Express Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

PetMed Express's Cash from Financing for the fiscal year that ended in Mar. 2023 is calculated as:

PetMed Express's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PetMed Express  (NAS:PETS) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

PetMed Express's issuance of stock for the three months ended in Dec. 2023 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

PetMed Express's repurchase of stock for the three months ended in Dec. 2023 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

PetMed Express's net issuance of debt for the three months ended in Dec. 2023 was $0.0 Mil. PetMed Express received $0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

PetMed Express's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. PetMed Express paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

PetMed Express's cash flow for dividends for the three months ended in Dec. 2023 was $-0.0 Mil. PetMed Express spent $0.0 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

PetMed Express's other financing for the three months ended in Dec. 2023 was $0.0 Mil. PetMed Express received $0.0 Mil on other financial activities.


PetMed Express Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of PetMed Express's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


PetMed Express (PetMed Express) Business Description

Traded in Other Exchanges
Address
420 South Congress Avenue, Suite 100, Delray Beach, FL, USA, 33445
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies primarily to retail consumers.
Executives
Gian Fulgoni director
Christine Chambers officer: CFO 1501 1ST AVENUE SOUTH, STE. 600, SEATTLE WA 98134
Mathew N Hulett director, officer: CEO & President 1621 NORTH KENT STREET, SUITE 1200, ARLINGTON VA 22209
Campbell Leslie C.g. director C/O COUPA SOFTWARE INC., 1855 S. GRANT STREET, SAN MATEO CA 94402
Diana G Purcel director C/O FAMOUS DVES OF AMERICA INC, 8091 WALLACE ROAD, EDEN PRAIRIE MN 55344
Moseley Mark Bradley Jr other: Chief Technology Info Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Daniel Job Pingree other: Chief Marketing Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Sandra Yvette Campos director 4900 E DUBLIN GRANVILLE RD, COLUMBUS OH 43081
Jacqueline Paula Smith other: Vice President of People 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Carolyn Carden other: VP of Product 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Peter Cobb director DSW, INC., 810 DSW DRIVE, COLUMBUS OH 43219
Jodi Watson director 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Frank J Formica director 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069
Bruce S Rosenbloom officer: Chief Financial Officer 6401 CONGRESS AVENUE, SUITE 250, BOCA RATON FL 33487
Menderes Akdag director, officer: Chief Executive Officer 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069